Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance

Anti-Cancer Drugs

Volumn 22, Issue 9, 2011, Pages 940-943

  Gerullis, Holger ^a,b,d   Ecke, Thorsten Holger ^c   Janusch, Barbara ^a   Arndt, Christian ^d   Heidari, Marcel ^a   Oniani, Jaba ^a   Otto, Thomas ^a,b,d  

^a Lukaskrankenhaus GmbH   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c HELIOS Klinikum Bad Saarow   (Germany)

^d German Centre for Assessment and Evaluation of Innovative Techniques in Medicine (DZITM)   (Germany)

Author keywords

second line; temsirolimus; third line; transitional carcinoma; urothelial carcinoma; vinflunine

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; TEMSIROLIMUS; VINFLUNINE;

ADULT; ADVANCED CANCER; ARTICLE; BLADDER CANCER; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CAUCASIAN; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; DEATH; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; LIVER METASTASIS; LYMPH NODE METASTASIS; LYMPHEDEMA; MEDIASTINUM LYMPH NODE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 80052486872     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328347a86a     Document Type: Article

References (15)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009; 59:225-249
2. Von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068-3077
3. Sternberg CN, Yagoda A, Scher HI,Watson RC, Herr HW, Morse MJ, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988; 139:461-469 (Pubitemid 18082866)
4. Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15:2564-2569 (Pubitemid 27289886)
5. Bellmunt J, Albiol S. Chemotherapy for metastatic or unresectable bladder cancer. Semin Oncol 2007; 34:135-144 (Pubitemid 46436117)
6. Sternberg CN, De Mulder PH, Schornagel JH, Théodore C, Fossa SD, Van Oosterom AT, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol no. 30924 J Clin Oncol 2001; 19:2638-2646 (Pubitemid 32441368)
7. Bellmunt J, Thé odore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27:4454-4461
8. Gerullis H, Ecke T, Eimer C, Wishahi M, Otto T. Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review. Anticancer Drugs 2011; 22:9-17
9. Mamtani R, Vaughn DJ. Vinflunine in the treatment of advanced bladder cancer. Expert Rev Anticancer Ther 2011; 11:13-20.
10. Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II national cancer institute trial. J Clin Oncol 2007; 25:2218-2224 (Pubitemid 46954646)
11. Wülfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009; 115:2881-2890.
12. Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010; 28:1373-1379
13. Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ,Wilding G. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the eastern cooperative oncology group. Cancer 2009; 115:4090-4095
14. Wu X, Obata T, Khan Q, Highshaw RA, De Vere White R, Sweeney C. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 2004; 93:143-150. (Pubitemid 38112985)
15. Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, Kassouf W. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther 2009; 8:2339-2347